Canada Markets closed

Graybug Vision, Inc. (GRAY)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.2600-0.0300 (-1.31%)
At close: 04:00PM EST
2.2100 -0.05 (-2.21%)
After hours: 05:08PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close2.2900
Open2.2500
Bid2.2700 x 800
Ask2.3000 x 1100
Day's Range2.2100 - 2.3200
52 Week Range2.2100 - 35.1800
Volume145,471
Avg. Volume182,843
Market Cap47.586M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar. 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.75
  • GlobeNewswire

    Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

    BALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will participate in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will be available on the conference website beginning at 10 a.

  • GlobeNewswire

    Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2021, and Recent Corporate Developments

    BALTIMORE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate developments and reported financial results for the three and nine months ended September 30, 2021. Recent Corporate Developments Analysis of Data from Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMD —

  • GlobeNewswire

    Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting

    BALTIMORE, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced two clinical data presentations at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting to be held on November 12-15, 2021 in New Orleans, Louisiana, as well as a company presentation at the Eyecelerator@AAO 2021 event on November 11, 2021: